Resmed Completes $340M Acquisition of Noctrix Health

Why It Matters

The deal diversifies ResMed’s portfolio beyond sleep‑apnea equipment into a fast‑growing neuromodulation market, creating a new revenue stream and addressing an unmet therapeutic need for millions of Americans.

Key Takeaways

• ResMed paid $340 M for Noctrix, adding RLS device.
• Noctrix’s Nidra device shows 61% response in trials.
• RLS affects ~17 M Americans, largely untreated by drugs.
• Nidra fits ResMed’s home‑medical‑equipment distribution network.
• Noctrix generates $24 M annual revenue with high margins.

Pulse Analysis

ResMed’s $340 million purchase of Noctrix Health marks a strategic pivot from its traditional sleep‑apnea focus to the broader neuromodulation arena. The acquisition gives the company control of Nidra, a non‑invasive nerve‑stimulation system that received de novo FDA clearance in 2023. With an estimated 17 million U.S. adults living with restless‑legs syndrome, the market potential dwarfs ResMed’s existing sleep‑device base, offering a high‑growth avenue that aligns with the firm’s expertise in home‑based respiratory care.

The therapeutic landscape for RLS is dominated by dopamine agonists, which carry significant side‑effects and limited long‑term efficacy. Clinical trials of Nidra reported a 61% symptom‑response rate after four weeks, far outpacing the 16% placebo effect and underscoring a clear clinical advantage. By integrating Nidra into its established durable‑medical‑equipment distribution channels, ResMed can tap into existing relationships with sleep physicians and home‑care providers, accelerating adoption and reimbursement pathways that typically stall new device entrants.

From an investor standpoint, the acquisition diversifies ResMed’s revenue mix, adding a high‑margin, early‑stage product line with a projected compound annual growth rate well above the company’s legacy CPAP segment. The $24 million run‑rate of Noctrix, combined with ResMed’s scale, suggests the potential to lift overall earnings per share within the next few years. Moreover, the move signals to the market that ResMed is positioning itself as a broader sleep‑and‑neurology platform, a narrative that could attract strategic partners and bolster long‑term valuation.

Deal Summary

Resmed closed a $340 million acquisition of Noctrix Health, adding the Nidra device for restless‑legs syndrome to its portfolio. The deal gives Resmed control of a non‑invasive treatment and leverages its sleep‑therapy distribution channels. Noctrix, with a $24 million revenue run‑rate, will benefit from Resmed’s market access and scaling capabilities.